Spero Therapeutics Inc (SPRO)

[saigai]

shorts in control...profits still being withdrawn

[saigai]

consolidation or chinese water torture a little of both

[StockLogistics]

Last time at these cash levels was December 2021 after the 66 million from GSK, how then to factor in current overall market conditions when there is an equivalent to better outlook for a company, possibly minus 50% across all companies from December ‘21 SP to today, all things being equal. For SPRO profit outlook is actually better now than it was then imo.

[Here Today]

Yeah, DOW heading to a big recession correction if it keeps dipping lower. A lot of eyes watching the DOW and if it breaks below 29k

[saigai]

another rough mkt day.. but im comfy holding this one

[Here Today]

Nice continuation of volume action this morning. Let’s see if the MM’s allow it to run at any point today.

[saigai]

go spro...

[StockLogistics]

“4:52a ET 9/23/2022 - Dow Jones
Spero Therapeutics Raised to Outperform From In-Line by Evercore ISI Group

Ratings actions from Benzinga: https://www.benzinga.com/stock/SPRO/ratings

(END) Dow Jones Newswires

September 23, 2022 04:52 ET (08:52 GMT)”

“4:42a ET 9/23/2022 - Benzinga
Evercore ISI Group Upgrades Spero Therapeutics to Outperform, Raises Price Target to $8

Evercore ISI Group analyst Josh Schimmer upgrades Spero Therapeutics (NASDAQ:SPRO) from In-Line to Outperform and raises the price target from $2 to $8.

Latest Ratings for SPRO DateFirmActionFromTo

Oct 2021OppenheimerDowngradesOutperformPerform Jan 2021HC Wainwright & Co.MaintainsBuy Dec 2020BerenbergInitiates Coverage OnBuy

View More Analyst Ratings for SPRO

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”

[StockLogistics]

Making a 66 million deal up front with GSK to recapitalize to December 2021 levels seems to be effective, as is the resubmission to the FDA after another phase 3 trial, they also restructured to save on labor costs, they have other drugs they are working on as well including a Q4 result pending, and your statements about their losses were proven to be incorrect, yet you continue to restate the same statement.

[Here Today]

Let’s see a nice Power Hour move!!!

[dshade]

another strong move on that GSK news. nice

[Wolfofwitz]

Perfect getting for round 3...

[Here Today]

About to hit 200 million in share volume and they are holding this stock down like the horse rider in Easy Money purposely trying to lose the trotter race…..

[Here Today]

MM’s Holding this down…..

[knrorrel]

nice dip add. 2.46

[Triple nickle]

Filled again at 2.60

[subslover]

Tomorrow? We traded $3.18 about 1/2 hour ago

[Wolfofwitz]

Maybe tomorrow

[Invest-in-America]

SPRO: Well, see-ya-all up on Planet MARS a little later today, Peeps!!! (Long before old Elon Muskrat ever RETIRES up there.)

[Invest-in-America]

SPRO: "Starting to dip"????? WHAT??? Dip to the MOON, Dude!!! Gonna have a circa 2,000% UP, MECHA-GODZILLA-CLASS runner here today, Bro!!

[subslover]

POW! $3.18

[Triple nickle]

Starting to dip

[Invest-in-America]

SPRO: Last chance to grab this was when it hit 170% UP; this will Close today UP by circa 700%+++++!!! WHY??? Because there ain't SHIT else out there!!! EVERYONE around this Planet is running to THIS ONE today!!

[subslover]

New highs are ready to trade!

[Here Today]

Float I believe is less than 25 million shares!!!

[Here Today]

Traded 3x’s Outstanding Share Count already.

[Here Today]

Bought the dip, now for the Rocket Rip higher!

[make it happen]

Lucky anyone was able to dump their bag for 10%

And clear path to Profitability? How? Lol

Negative in every aspect Profitability, Cash Flow Statement, Income Statement & Managment Effectiveness.

[StockLogistics]

You made a false claim proven to be false.

[StockLogistics]

Usually if a deal is bad the stock will sell off at the open, that hasn’t happened today, therefore, the deal is not seen as bad imo.

[make it happen]

It's delinquent either way and the volume is not sustainable

It doesn't meet the nasdaq requirements

[StockLogistics]

So you agree that your numbers were incorrect.

On 9/6 this stock traded 80 million shares to 1.90, many of those shares are taking their 10% gain so far today. They are frustrated after two weeks of losses and you can’t blame them for selling, but the numbers indicate a recapitalization to December 2021 levels and a clear path to profitability after May restructuring reduced expenses.

[make it happen]

That's bot good. Loses went up approx 60% yoy

[StockLogistics]

Your claim that they lost 132 million last quarter doesn’t reflect the actual numbers, as posted in my previous post.

[make it happen]

Enterprise value has been negative millions for some time.

Price reflects doesn't meet requirements, filings and is delinquent.

How can you loss $132,000,000 a quarter or over $500,000,000 a year. Any cash will be gone in a month and this deals already done so could have burnt through half of it if not more already...

https://finance.yahoo.com/quote/SPRO/key-statistics?p=SPRO

[StockLogistics]

Your assessment of the company does not appear to correlate to the actual numbers:

“Lol. Well if losing over $132,000,000 in one quarter that plus cash and more will be gone in less than 1 quarter.”

Actual numbers:

“Second Quarter 2022 Financial Results

Spero reported a net loss for the second quarter ended June 30, 2022 of $28.7 million or $0.87 per common share, compared to a net loss of $18.6 million or $0.63 per common share reported for the same period in 2021.”

[make it happen]

Lol. Well if losing over $132,000,000 in one quarter that plus cash and more will be gone in less than 1 quarter.

66
+45
=111
-132
=-22

Simple math still negative 22 million. Then 3 more quarters of $-132Mil till Phase 3... Then how long plus how many more years for phase 3 and beyond to be completed.

It's delinquent js

[StockLogistics]

Assets:liabilities is 3:1, cash was down 67 million in six months from December to June, and they just recouped that money in the upfront payment of the GSK deal:

https://www.otcmarkets.com/filing/html?id=16006454&guid=FkX-kFGGBz2pJth

Shareprice in December 2021 was $15.00.

[MMMQA]

I guess GSK should have consulted you before they just threw away 66 million up front.

[make it happen]

Phase 3 end of 2023 is more than a year. Look at how much money they are hemorrhaging a quarter. Litterally like $500,000,000 million a year half a billion... $100 mill and change a quarter. It's like a broken dam that's about to break.

Phase 3 is the begginging. Still has FDA which was already declined. Then a whole ton of other processes before anything. As you mentioned it's on Spero not GSK. They are just going to file some paper work like you said "filings". They just get paid. While SPRO loses approximately 1/2 billion dollars a year.

As a delinquent stock

Do you see any positive #'s

Profitability
Operating Margin-957.08%

Management Effectiveness
Return on Assets -64.45%
Return on Equity -179.55%

Cash Flow
Operating Cash Flow -83.56M
Levered Free Cash Flow -49.85M

Growth (yoy) -61.30%
Gross Profit. -42.11M
EBITDA. -93.64M
Net Income to Common -113.27M

[subslover]

That's huge!!

[StockLogistics]

Volume > OS premarket

Forward looking market:

“Spero expects to start a new phase 3 trial in 2023, following encouraging FDA regulatory feedback on the proposed trial design.

Spero will be responsible for the execution and costs of the follow-up Phase 3 trial of tebipenem HBr. GSK will be responsible for the execution and costs of additional development, including Phase 3 regulatory filing and commercialization activities.”

GSK sees something in the data that indicates likely profits for all parties imo, the market usually looks forward as per usual market dynamics.

“Spero had a cash balance of $45.4 million. The company believes its current cash runway will be sufficient to fund it beyond 2024.“

You stated they would run out of cash in one month, there appears to be a wide gap of opinions, one from the company itself, and another opinion.

[make it happen]

Profitability
Operating Margin-957.08%

Management
Return on Assets -64.45%
Return on Equity -179.55%

Cash Flow
Operating Cash Flow -83.56M
Levered Free Cash Flow -49.85M

Growth (yoy) -61.30%
Gross Profit -42.11M
EBITDA -93.64M
Net Income to Common -113.27M

[make it happen]

Dude that's so incorrect. The amount of capital burn this company has with a product the fda declined is wild.

losing hundreds of millions $100,000,000's a quarter

FDA Food and Drug Administration declined approval of Tebipenem

Plans "Late stage trial end of 2023" - hasn't done anything with it yet

Will burn threw the "investment" 20x by that time or 1 month

It's delinquent..

[StockLogistics]

“Lock-Up. From and including the Effective Date until the date that is twenty-four (24) months from and after the Effective Date (the “Lock-up Period”), and subject to customary exceptions, neither GGL nor its affiliates shall sell or otherwise dispose of the Shares, or any other shares of Common Stock owned beneficially by GGL and/or its affiliates (collectively, the “Locked-Up Shares”), provided, however, such Lock-up Period shall expire from and after eighteen (18) months after the Effective Date, with respect to 50% of the Locked-Up-Shares.”

[StockLogistics]

“Spero will receive an upfront payment of $66 million and milestone payments of $225 million.
GSK has also agreed to take an equity stake in Spero, purchasing 7.45 million shares at approximately $1.20805 per share, not to exceed 19.99% ownership of Spero by GSK.
As of June 30, Spero had a cash balance of $45.4 million. The company believes its current cash runway will be sufficient to fund it beyond 2024.“

Share Structure

Market Cap Market Cap
28,814,946
09/21/2022
Authorized Shares
Not Available
Outstanding Shares
35,067,477
08/05/2022
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available
Par Value
Not Available

291 million / 35 million = $8.31

[PStockPickz]

$2.25 up !

[PStockPickz]

No problem crushing resistance levels.

[Invest-in-America]

SPRO: Indeed!! But it sure backed-down yesterday, after hitting that glorious HIGH.

[INFINITI]

Looks like round 2